Antibiotics in the clinical pipeline at the end of 2015

MS Butler, MAT Blaskovich, MA Cooper - The Journal of antibiotics, 2017 - nature.com
There is growing global recognition that the continued emergence of multidrug-resistant
bacteria poses a serious threat to human health. Action plans released by the World Health …

Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection

HY Ng, WK Leung, KS Cheung - International Journal of Molecular …, 2023 - mdpi.com
Despite the declining trend of Helicobacter pylori (H. pylori) prevalence around the globe,
ongoing efforts are still needed to optimize current and future regimens in view of the …

Structural characterization of the millennial antibacterial (fluoro) quinolones—sha** the fifth generation

A Rusu, IA Lungu, OL Moldovan, C Tanase, G Hancu - Pharmaceutics, 2021 - mdpi.com
The evolution of the class of antibacterial quinolones includes the introduction in therapy of
highly successful compounds. Although many representatives were withdrawn due to …

Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review

GM Buzás, P Birinyi - Antibiotics, 2023 - mdpi.com
Although discovered 40 years ago, Helicobacter pylori infection is still raising diagnostic and
therapeutic problems today. The infection is currently managed based on statements in …

Efficacy of tegoprazan for improving the susceptibility of antimicrobial agents against antibiotic-resistant Helicobacter pylori

JW Lee, N Kim, RH Nam, JE Yu, JH Son… - Gut and …, 2020 - pmc.ncbi.nlm.nih.gov
Background/Aims Favorable outcomes of potassium-competitive acid blocker (PCAB)-
containing eradication therapy have been reported. In fact, tegoprazan, a recently …

Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella …

H Chalhoub, SV Harding, PM Tulkens… - Clinical Microbiology …, 2020 - Elsevier
Abstract Objectives Burkholderia pseudomallei, Yersinia pestis and Francisella tularensis
are facultative intracellular bacteria causing life-threatening infections. We have (a) …

Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication

JW Lee, N Kim, RH Nam, SM Lee… - Journal of …, 2019 - Wiley Online Library
Abstract Background and Aim Failure of bismuth quadruple therapy for Helicobacter pylori
eradication is frequently observed. To increase the eradication rate, comprehensive …

[HTML][HTML] In Vitro Susceptibility and Synergistic Effect of Bismuth Against Helicobacter pylori

J Woo, CS Bang, JJ Lee, JY Ahn, JM Kim, HY Jung… - Antibiotics, 2024 - mdpi.com
Background/objectives: Bismuth is commonly used in Helicobacter pylori (H. pylori)
eradication therapy. However, few studies have examined the in vitro susceptibility of H …

Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in …

SY Rhie, JY Park, TS Shin, JW Kim, BJ Kim, JG Kim - Antibiotics, 2020 - mdpi.com
The efficacy of fluoroquinolone-based eradication therapy largely depends on the
fluoroquinolone resistance of H. pylori. The aim of this study was to investigate the changes …

Fluoroquinolone and Rifabutin-Containing Therapy

JW Lee - Helicobacter pylori, 2024 - Springer
Fluoroquinolone-containing therapy and rifabutin-containing therapy are regimens which
use proton pump inhibitor and amoxicillin as it is in clarithromycin-containing triple therapy …